Which factors influence the participation in statutory skin cancer screenings in Germany?

BACKGROUND AND OBJECTIVES: Due to increasing skin cancer incidence, Germany implemented a statutory nationwide routine skin cancer screening (rSCS) in 2008. The present study aims (1) to analyze which patient factors are associated with the participation in rSCS in Germany and (2) to investigate reasons for nonparticipation. PATIENTS AND METHODS: Participants and nonparticipants of rSCS (≥ 35 years) were recruited in routine care in nine dermatological outpatient clinics. Reasons for (non-)participation, knowledge about skin cancer as well as clinical and socioeconomic data were obtained. Stratified by groups, descriptive analyses and binary logistic regression analyses for associations with participation were performed. RESULTS: Of the 294 rSCS participants and 162 non-participants, 46.5% were male with a mean age of 54.5 ± 12.7 years. In total, 87.1% had sunburns in childhood and 47.1% used sunbeds before. Higher age, female gender, previous sunbed use, and concern for and knowledge of skin cancer were significantly associated with previous rSCS participation. Of the non-participants, 46% were unaware of the option for free rSCS and 40% justified their nonparticipation on the basis of feeling healthy. CONCLUSIONS: The reasons for nonparticipation in rSCS, such as sociodemographic characteristics and risk behavior, should be known in order to optimize rSCS programs.

The Value of Hybrid Teledermatology in German Prisons: Analysis of Routine Telemedical Data.

Introduction: German prisons face organizational and time-consuming difficulties in access to medical specialties. Since 2019, our institute offers interdisciplinary video consultations with spatially independent dermatological support for German prisons. Methods: Documentation of n = 200 consultations between February 2020 and July 2021 with retrospective analysis of dermatological conditions and consultation requests. Results: Most cases (98.0%; 196 of 200) were performed during a regular weekly teleclinic and only few cases on urgent demand. The average duration of the skin disease before request for consultation was 10.3 ± 26.9 months (mean ± standard deviation), the majority had first onset of their disease or acute recurrence of previously known skin diseases. With respect to medical complaints, 39.7% of patients reported severe itch and 7.7% indicated severe pain. For most cases (84.0%), topical treatment and for almost one-third (32.5%) we recommended systemic treatment. The predominant number of cases was only presented once (92.0%) and further treatment of the skin disease could be managed by the medical staff inhouse. Only few consultations could not be solved virtually and were referred to local physicians for face-to-face consultations or procedures. Discussion: Teledermatological care for prisoners effectively supports the inhouse medical resources of prisons. Our interdisciplinary approach enables general practitioners and medical staff of the respective prison to manage the case and shortens the time period until therapy starts.

[Epidemiology of scabies in Germany: multisource analysis of primary and secondary data]. / Epidemiologie der Skabies in Deutschland: Multi-Source-Analyse von Primär- und Sekundärdaten.

BACKGROUND: Scabies is one of the most common and, in terms of burden of disease, one of the most significant skin diseases worldwide. In Germany, an increase in cases is currently being discussed, for which reliable data have been lacking until now. OBJECTIVES: The goal is to clarify the prevalence and treatment of scabies in Germany. MATERIALS AND METHODS: Multisource analyses of treatment data from a nationwide statutory health insurance company, the Federal Statistical Office and company skin screenings. RESULTS: In Germany, the number of cases of scabies has been rising since 2009 and especially since 2014. In the outpatient setting, there was an increase of 52.8% to around 128,000 treatment cases between 2010 and 2015. Currently, more than 11,000 inpatient cases are documented annually in Germany with scabies as the main diagnosis (ICD-10 B86). The increase between 2010 and 2016 was about 306%. The main outpatient specialist groups providing care are dermatologists and general practitioners, while in the inpatient sector treatment is provided by departments of dermatology, paediatrics and internal medicine. CONCLUSION: Due to the aforementioned development of prevalence and incidence, the need for care will remain at a high level in the future, which suggests an increased need for education and early detection.

Status quo and perspectives of dermatology hospitals in Germany: spectra of health care and staff situation.

BACKGROUND: Inpatient care in Germany has been subject to change since the introduction of the DRG-based payment system. There have been no publications on important differentiating factors such as the spectrum of care and the staffing situation in dermatology. METHODS: Health care analysis of 115 dermatology hospitals in October 2019 using a structured survey questionnaire. RESULTS: On average, the spectrum of care included 31.0 % general dermatology, 33.6 % surgical dermatology, 15.6 % oncology, and 10.1 % allergology. The clinics had an average of 14 full-time positions and 3 part-time positions (university clinics: 23/5, non-university clinics: 9/2). The mean nationwide proportion of women in the physician teams showed the following distribution: postgraduate physicians 73.3 %, senior physicians 53.0 %, directors 20.0 %. The applicant situation of senior physicians and specialists was assessed as predominantly poor, that of residents as predominantly good. Worse applicant situations were present in non-university hospitals and in rural areas. The satisfaction of the medical directors with the current conditions of inpatient care showed a variable assessment independent of university hospital and non-university hospital status. However, the threat to inpatient care was predominantly assessed as low (71.6 %). CONCLUSIONS: The overall situation of inpatient dermatological care can be classified as predominantly good. In addition, the majority of dermatology clinics provide a wide range of care with regard to the variety of indications. The general conditions, which in some cases are rated as inadequate, require further measures.

Structures and performance characteristics of dermatology hospitals in Germany. Current status and long-term development.

BACKGROUND: The objective of the study was to characterize the performance of German dermatology hospitals. METHODS: A structured survey questionnaire was sent out to all dermatology hospitals in October 2019 as part of a cross-sectional analysis based on health care research. RESULTS: Of the 115 hospitals, 95 (82.6 %) responded, including 34 (35.8 %) university hospitals (UC) and 61 (64.2 %) non-university hospitals (NUC), of which 78 % were urban (43 % UC, 57 % NUC) and 22 % rural (10 % UC, 90 % NUC). The dermatology departments comprised an average of 45 inpatient and 11 day-care beds (UC: 52/13, NUC: 40/9). An average of 2,302 inpatients were cared for in 2018 (UC: 2,874, NUC: 1,983), and the case mix index was 0.76 (UC: 0.74, NUC: 0.77, overall range: 0.40-0.96). Mean length of stay was 5.5 days for UC, relevantly lower than 2013 (5.9 days) and 2011 (7.1 days) data, and also significantly lower for NUC at 5.9 (2018) versus 5.1 days (2013). CONCLUSIONS: German dermatology hospitals continue to have a high volume of inpatient care, with a comparison of the last six years again showing a compression with shorter length of stay and higher occupancy density. Dermatological hospitals represent an essential pillar of dermatological care.

Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs.

BACKGROUND: In Germany, skin diseases are mainly treated in the 115 dermatological hospitals. METHODS: Health care and health economic analysis of dermatological inpatient care and prediction of future care needs based on primary and secondary data. RESULTS: Outpatient and inpatient care for dermatologic treatment indications is predominantly provided by dermatology specialists. Inpatient treatment was provided for 833,491 cases in 2018, corresponding to 4.21 % of all inpatient cases (19,808,687). Most common treatment cases were: epithelial skin cancer (total 87,386, of which dermatology clinics 52,608), followed by melanoma (23,917/17,774), psoriasis (19,291/13,352), erysipelas (73,337/11,260), other dermatitis (12,671/10,842), atopic dermatitis (AD) (11,421/9,734), and herpes zoster (26,249/9,652). With an average length of stay of 5.69 days, dermatology hospitals were in the bottom third. The proportion of inpatient indications cared for in dermatology hospitals was highest for prurigo (95.2 %), pemphigus (94.9 %), parapsoriasis (94.6 %), pemphigoid (90.3 %), eczema other than AD (85.6 %), and AD (85.2 %). While the total number of inpatient treatment cases in Germany has increased by an average of 17.5 % between 2000 and 2018, this is the case for 26.6 % of skin diseases and over 150 % for individual ones. The projection of current to future inpatient care suggests a continued high demand for inpatient care by dermatology hospitals. CONCLUSION: Inpatient dermatological care will continue to be an indispensable component of qualified, socially necessary care in Germany.

[Access to statutory skin cancer screening : Organizational and regional factors in Germany]. / Zugang zum gesetzlichen Hautkrebsscreening : Organisatorische und regionale Faktoren in Deutschland.

BACKGROUND: In 2008, statutory skin cancer screening (gesetzliches Hautkrebsscreening, gHKS), conducted by dermatologists or general practitioners, was introduced in Germany. The aim was earlier detection of cancer and therefore improved health care delivery. To assess the success of the gHKS and to increase utilization, the opinion of the population on access to the gHKS is of great relevance. OBJECTIVES: The study examines administrative and regional factors of access to the gHKS in Germany. MATERIALS AND METHODS: In this cross-sectional study, a nationwide survey was conducted among statutory health insured persons aged 18 and over. They were interviewed by telephone about the gHKS with focus on the access to the gHKS. Descriptive statistics and subgroup analysis based on sociodemographic variables and physician specialties were performed. RESULTS: Overall, 1015 people were interviewed, of whom 359 (35.4%) had already utilized the gHKS. Most of them (38.3%) were informed about this service by their general practitioner. Most respondents (70%) preferred having the dermatologists conduct the screening and more participants consulted the dermatologist than the general practitioner for it (76% vs. 24%). At the dermatologist, the travel time to the gHKS was more often longer than 30 min (12% vs. 1%, p < 0.05) and the waiting times for appointments were more often longer than 2 weeks (67% vs. 18%, p < 0.05). Regional differences were identified for travel times and the choice of travel modalities. CONCLUSIONS: The participants of the study preferred having a dermatologist conduct the gHKS. The dermatologist was also consulted more frequently by the gHKS participants. However, access in terms of travel and waiting times for the gHKS was longer at the dermatologist than at the general practitioner.

Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest.

Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.